PEOPLE
Meet the Team
EXECUTIVE TEAM
EXECUTIVE TEAM
Maurie Stang
Maurie has a 25 year track record of building and managing successful companies in the Australian healthcare market. He has significant operational experience and an extensive network within the life-sciences, pharmaceutical and finance sectors, both in Australia and internationally.
Aside from his role as Principal of Gryphon Capital, Maurie is Managing Director of Regional Healthcare Group. Since he co-founded Regional, the Group has grown into one of the region’s leading healthcare product suppliers, and is today among the largest privately held companies in its sector. Maurie is also a Director of Novapharm Research and of Nanosonics.
ADVISORY BOARD
ADVISORY BOARD
Steven Kritzler, M.Sc
Steve has 35 years experience in commercial R&D in the areas of pharmaceutical, medical, cosmetic and specialty industrial products. Steve is a director of Novapharm Research and under his current technical direction, the company has become a world-leading source of infection control technology. He holds 16 international patents, with a variety of products emanating from these patents now in general use worldwide. Steve holds an M.Sc from UNSW in the field of Polymer Chemistry, and is a member of the Disinfectant Working Group for the Therapeutic Goods Assosciation. Steve is a Director of Novapharm Research and of Nanosonics.
ADVISORY BOARD
Ian Ernst, B.A, B.Sc, Ph.D, MRACI, FIPAA
Ian is a Registered Patent Attorney with a background in industrial chemistry spanning 40 years.
He entered the patent profession in 1979 and from 1982 to 1995 was a Partner in a leading Australian firm of Patent and Trade Mark Attorneys. Since then he has acted as a consultant.
Ian has had more than 20 years experience specialising in intellectual property including patent drafting, prosecution, and conflict in Australia and in other Jurisdictions. His primary academic qualifications were gained in the fields of Economics and Industrial Chemistry, although he later specialised in Physical Chemistry.
Prior to 1982 Ian held positions of responsibility in several large organizations, including a spell as the Chief Executive Officer of a multinational company.
ADVISORY BOARD
Dr Yann Gambin
Dr Yann Gambin is a Senior Lecturer at UNSW, and an EMBL Australia group Leader.
After a PhD in biophysics in Paris, he went on for a first postdoc at the Scripps Research Institute in San Diego. In 2010, he transitioned to a semi-independent position at the University of Queensland, under a Queen Elizabeth II fellowship. After an ARC Future Fellowship (2012-2017), he joined the EMBL Australia network, supported by ARC and NHMRC grants.
Dr Gambin has developed new single-molecule techniques to probe protein oligomerisation and protein-protein interactions, and applied these techniques to the detection of pathogens at the single molecule level. He has also been applying these techniques to probe key questions relating to cell biolog, particularly studying the self-association mechanisms that drive signalling in innate immunity. His recent outputs in terms of publications (11 publications in 2018, 3x Nature Communications in 2019), citations (> 250 cites/year) and invited contributions testify to a strong national and international standing.
In the last 5 years as an independent group leader at the University of New South Wales, he has developed an extensive library of human proteins, covering all pathways of innate immunity. His group uses state-of-the-art single molecule spectroscopy and imaging techniques, combined with high-efficiency cell-free expression system produced in house. He has now refocused his laboratory on studying the interference of viral proteins on these innate immune pathways, with two key projects focusing on SARS-CoV-2 and Nipah viruses.
ADVISORY BOARD
Dr Ivan Rajkovic
Dr Rajkovic joined the patent attorney profession in 1993, after a 17-year career in biomedical research, in both academic and commercial settings. He was a partner in a major Sydney-based intellectual property firm for 14 years, until his retirement from the firm in 2014. Dr Rajkovic currently advises companies in the life sciences field on patent portfolio structuring, patent filing strategies and portfolio management.
Dr Rajkovic’s career in biomedical research comprised over thirteen years post-doctoral academic research and a further four years of commercial research and development in the field of genetic engineering and bio-pharmaceuticals. His particular technical expertise lies in the areas of molecular immunology and oncology, biomolecular engineering, transgenics, gene therapy, microbial biochemistry, diagnostics and pharmaceuticals. Dr Rajkovic is the author of 45 publications in peer-reviewed scientific journals and books in the fields of molecular and cellular biology and immunology.
As a registered patent attorney, Dr Rajkovic has extensive experience in the intellectual property field, including drafting patent specifications, patent prosecution, oppositions and litigation support, intellectual property management and the commercialisation of intellectual property. He is a frequent speaker at national and international conferences in the field of biotechnology patenting, commercialisation and IP management.
COMMERCIAL
COMMERCIAL ANALYST
Daniel Stang
Daniel Stang is the Commercial Manager of Insite Molecular Biosciences. Mr Stang graduated from the University of Sydney with a Commerce-Science double degree in 2016, majoring in Finance and Biology.
During his career to date, Mr Stang had a short time at CHAMP Ventures, one of Australia’s leading Venture Capital firms before acquiring management experience in the Healthcare vertical of Zip Co. Ltd (ASX:ZML). At Vectus Biosystems (ASX:VBS) he gained experience in both drug synthesis and the development of next-generation Accugen for qPCR. He has a continuing role as a Biotech Analyst at Gryphon Capital, covering some of Australia’s leading Biotech and Medtech companies.